Aromatic formamide compounds, preparation methods and medical uses thereof

By designing and screening araformamide compounds, the taste interference problem of existing P2X3 receptor antagonists in the treatment of chronic cough was solved, and a novel compound with high antagonism activity was developed to treat diseases related to P2X3 activity, achieving Effective treatment of chronic cough and other diseases.

CN114072399BActive Publication Date: 2024-11-29NAT INST OF PHARMA R & D CO LTD

Patent Information

Application Number
CN202180004411.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-05-24
Publication Date
2024-11-29
Estimated Expiration
2041-05-24

AI Technical Summary

Technical Problem

Existing P2X3 receptor antagonists such as Gefapixant have side effects on taste interference in the treatment of chronic coughs and lack effective novel P2X3 antagonists to treat diseases associated with P2X3 activity.

Method used

A series of substituted araformamide compounds were designed and synthesized. By screening them for P2X3 activity, they were found to have outstanding P2X3 antagonistic activity for the development of new drugs to treat and prevent diseases associated with P2X3 activity.

Benefits of technology

These araformamide compounds show significant P2X3 antagonistic activity, which can effectively relieve pain and inflammatory pain without affecting taste, providing a new potential drug option for the treatment of chronic cough and other P2X3-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114072399B_ABST
    Figure CN114072399B_ABST
Patent Text Reader

Abstract

The present invention relates to aromatic carboxamide compounds, preparation methods and medical uses thereof. In particular, the present invention relates to compounds represented by general formula (I), preparation methods thereof and pharmaceutical compositions containing the compounds, and uses thereof as P2X3 receptor antagonists. The compounds and pharmaceutical compositions containing the compounds can be used to treat and / or prevent diseases associated with P2X3 activity, such as chronic cough, pain, endometriosis, overactive bladder, etc. The definitions of the substituents in the general formula (I) are the same as those in the specification.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and specifically relates to an aromatic carboxamide compound, a preparation method thereof, a pharmaceutical composition containing the aromatic carboxamide compound, and use of the aromatic carboxamide compound as a P2X3 receptor antagonist in the treatment and / or prevention of diseases associated with P2X3 activity. Background Art

[0002] ATP levels are elevated in pathological settings, indicating that it plays an important role in the pathogenesis of many diseases. In particular, ATP can drive and regulate various sensory behaviors and related responses. ATP has a greater impact on sensation when the body is stimulated (ultraviolet and chemical damage, etc.) or in a pathological state (asthma, bladder pain syndrome, etc.).

[0003] Many cell surface receptors (purinergic receptors) are involved in mediating the sensory signaling function of ATP, among which P2X3 is the main receptor that mediates the sensory effect of ATP. P2X3 receptors are ATP-gated cation channels and belong to the P2X receptor family, which also includes P2X1, P2X2, P2X4, P2X5, P2X6, and P2X7. P2X3 acts in the body in the form of homotrimer P2X3 or heterotrimer P2X2 / 3 (NeuroReport, 10, 1107-1111).

[0004] P2X3 and P2X2 / 3 are mainly expressed in small and medium diameter C- and Aδ-fiber sensory neurons in dorsal root ganglia (DRG) and cranial sensory ganglia, as well as peripheral nerve endings in the receptive fields of tissues such as skin, joints and viscera.

[0005] The P2X3 receptor is a member of the purine receptor family and is a non-selective ligand-gated ion channel. After being activated by ATP, it allows Na + , K + , Ca 2+ Through, especially Ca 2+ The permeability of the synaptic membrane is the most obvious, and it plays an important role in the generation and transmission of nociceptive information. When the body is injured or the nerves are damaged, a large amount of ATP is released, activating the presynaptic membrane P2X3 receptors, causing a large amount of Ca 2+ The increase in intracellular calcium concentration activates protein kinase A (PKA) and protein kinase C (PKC), which leads to the phosphorylation of PKA and PKC, and at the same time promotes the release of glutamate, further activating NMDA receptors, leading to the generation of excitatory postsynaptic currents and causing central sensitization.

[0006] Studies in various animal models have shown that P2X3 receptors play an important role in the process of nociception. For example, P2X3 receptor knockout significantly reduces pain responses. P2X3 receptor antagonists have anti-nociceptive effects in various models of pain and inflammatory pain. In addition to their prominent role in nociception and acute and chronic pain, P2X3 receptors have also been shown to be involved in the pathological processes of urogenital, gastrointestinal and respiratory diseases, especially overactive bladder and chronic cough. Therefore, P2X3 receptors play an important role in the pathological mechanisms of various diseases including pain, urogenital diseases, gastrointestinal diseases and respiratory diseases, and are ideal targets for the treatment of these diseases.

[0007] P2X3 subunits not only form homotrimers, but also form heterotrimers with P2X2 subunits. P2X3 subunits and P2X2 subunits are also expressed on the nerve fibers of the tongue, and receptors containing P2X3 and / or P2X2 subunits participate in taste transmission (bitter, sweet, salty, umami and sour). Studies have shown that P2X3 homotrimers are mainly involved in mediating nociception, while P2X2 / X3 heterotrimers are mainly involved in taste perception. Knockout animals lacking P2X2 and P2X3 subunits show reduced taste and even taste loss, while P2X3 subunit knockouts show mild or no changes in phenotype (J.Physiol.2015,593,1113-1125).

[0008] At present, the fastest-developed P2X3 receptor antagonist is the compound Gefapixant (AF-219) developed by Merck and Afferent (PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 115 (19), 4939-4944.), which is a non-selective antagonist of P2X3 and P2X2 / X3. It has shown significant efficacy in a Phase II clinical study on chronic cough, but also has the side effect of taste interference. This side effect is mainly attributed to the blocking of P2X2 / 3 heterotrimers. Therefore, there is a continuous need for new or improved P2X3 antagonists to develop new and more effective drugs for the treatment of chronic cough or other diseases related to P2X3. Summary of the invention

[0009] After intensive research, the inventors designed and synthesized a series of substituted aromatic carboxamide compounds and screened their P2X3 activity. The research results showed that the compounds have outstanding P2X3 antagonistic activity and can be developed as drugs for treating and / or preventing diseases related to P2X3 activity.

[0010] Therefore, the object of the present invention is to provide a compound represented by general formula (I) or its mesomorph, racemate, enantiomer, diastereoisomer, or mixture thereof, or a pharmaceutically acceptable salt thereof.

[0011]

[0012] in:

[0013] W 1 , W 2 , W 3 Each independently selected from CR 6 or N;

[0014] A 1 , A 2 , A 3 , A 4 , A 5 Each independently selected from C, N, O or S;

[0015] R 1 Selected from -NR a R b 、-NR a S(O) m R b 、-NR a S(O) m NR a R b 、-NR a S(O)(NR a )R b 、-NR a S(O)(NR a )NR b 、-NR a C(O)R b 、-NR a C(O)NR a R b 、-S(O) m R a 、-S(O) m NR a R b 、-S(O)(NR a )NR a R b 、-OR a 、-C(O)NR a R b 、-P(O)R a R b 、-(CR a R b )R b ;

[0016] Every R 2 are each independently selected from hydrogen, halogen, amino, nitro, cyano, hydroxyl, mercapto, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)R a 、-O(O)CR a 、-C(O)OR a 、-C(O)NR a R b 、-NHC(O)R a 、-S(O) m R a 、-S(O) m NR a R b 、-NHS(O) m R a ; wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl are optionally further substituted by one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, thiol, carboxyl, ester, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl;

[0017] R 3 is selected from aryl or heteroaryl; the aryl or heteroaryl is optionally further substituted by one or more groups selected from halogen, alkyl, haloalkyl, alkoxy, haloalkoxy;

[0018] L is selected from -C(R 4 R5)-;

[0019] R 4 and R 5 Each independently selected from hydrogen, alkyl, alkoxy; wherein the alkyl and alkoxy are optionally further substituted by one or more groups selected from halogen, amino, nitro, cyano, hydroxyl, thiol, carboxyl, ester, oxo, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl;

[0020] R 6 Selected from hydrogen, halogen, hydroxy, cyano, amino, carboxyl, ester, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally further substituted with one or more groups selected from halogen, amino, nitro, cyano, hydroxy, thiol, carboxyl, ester, oxo, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl;

[0021] R a and R beach independently selected from hydrogen, halogen, hydroxy, cyano, amino, carboxyl, ester, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally further substituted with one or more groups selected from halogen, amino, nitro, cyano, hydroxy, thiol, carboxyl, ester, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl;

[0022] or R a and R b Together with the atoms to which they are attached, they form a cycloalkyl or heterocyclyl group, which is optionally further substituted with one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, thiol, carboxyl, ester, alkyl, alkoxy, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl;

[0023] m is 0, 1 or 2;

[0024] n is an integer of 0-3.

[0025] In a preferred embodiment of the present invention, the compound represented by general formula (I) according to the present invention or its mesoform, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, is a compound represented by general formula (II) or its mesoform, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof,

[0026]

[0027] Among them, A 1 , A 2 , A 3 , A 4 , A 5 , R 1 , R 2 , R 3 , L, and n are as defined in the general formula (I).

[0028] In another preferred embodiment of the present invention, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein:

[0029] Group is selected from pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl, triazolyl or tetrazolyl, preferably pyrazolyl, thiazolyl, oxazolyl or 1,3,4-oxadiazolyl, more preferably thiazolyl;

[0030] The By n R 2 replaced by;

[0031] R 2 and n are as defined in the general formula (I).

[0032] In another preferred embodiment of the present invention, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereoisomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein R 3 C6-C 10 Aryl or 5- to 10-membered heteroaryl, preferably phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, more preferably pyrimidinyl, wherein the aryl or heteroaryl is optionally further substituted by one or more groups selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy.

[0033] In another preferred embodiment of the present invention, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein:

[0034] R 1 Selected from -NR a R b 、-NR a S(O) m R b 、-NR a S(O) m NR a R b 、-NR a S(O)(NR a )R b 、-NR a S(O)(NR a )NR b 、-NR a C(O)R b 、-NR a C(O)NR a R b 、-S(O) m R a 、-S(O)m NR a R b 、-S(O)(NR a )NR a R b 、-OR a 、-C(O)NR a R b 、-P(O)R a R b 、-(CR a R b )R b , preferably -NR a R b 、-NR a S(O)2R b 、-NR a S(O)(NR a )R b 、-NR a S(O)2NR a R b 、-NR a S(O)(NR a )NR b 、-NR a C(O)R b 、-NR a C(O)NR a R b 、-S(O)R a 、-SO2R a 、-S(O)2NR a R b 、-S(O)(NR a )NR a R b 、-OR a 、-P(O)R a R b ;

[0035] R a and R b Each is independently selected from hydrogen, halogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl is optionally further substituted by one or more groups selected from halogen, amino, nitro, cyano, hydroxyl, thiol, carboxyl, ester, oxo, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl;

[0036] or R a and R bTogether with the atoms to which they are attached, they form a 5- to 8-membered heterocyclic group, which is optionally further substituted with one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, thiol, carboxyl, ester, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroaryl;

[0037] m is 0, 1 or 2.

[0038] In a preferred embodiment of the present invention, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein:

[0039] R 1 Selected from -NR a R b ;

[0040] R a Selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, in particular cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or 5-8 membered heterocyclyl, in particular oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, wherein the C1-C6 alkyl, C3-C6 cycloalkyl, 5-8 membered heterocyclyl is optionally further substituted by one or more groups selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy;

[0041] R b Selected from hydrogen or C1-C6 alkyl.

[0042] In another preferred embodiment of the present invention, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein:

[0043] R 1 Selected from -NR a R b ;

[0044] R a and R b Together with the nitrogen atom to which they are attached, they form a 5- to 8-membered heterocyclic group, preferably a tetrahydropyrrolyl, a piperidinyl, a piperazinyl, a morpholinyl, or an 8-membered spiroheterocyclic group; the heterocyclic group is optionally further substituted by one or more groups selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy.

[0045] In another preferred embodiment of the present invention, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein:

[0046] R 1 Selected from -S(O)R a or-SO2R a ;

[0047] R a Selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, especially cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or 5-8 membered heterocyclyl, especially oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, wherein the C1-C6 alkyl, C3-C6 cycloalkyl, 5-8 membered heterocyclyl is optionally further substituted by one or more groups selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy.

[0048] In another preferred embodiment of the present invention, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein:

[0049] R 1 Selected from -S(O)2NR a R b ;

[0050] R a Selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, in particular cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or 5-8 membered heterocyclyl, in particular oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, wherein the C1-C6 alkyl, C3-C6 cycloalkyl, 5-8 membered heterocyclyl is optionally further substituted by one or more groups selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy;

[0051] R b Selected from hydrogen or C1-C6 alkyl;

[0052] Or, R a and R b Together with the nitrogen atom to which they are attached, they form a 5- to 8-membered heterocyclic group, preferably a tetrahydropyrrolyl, a piperidinyl, a piperazinyl, a morpholinyl, or an 8-membered spiroheterocyclic group; the heterocyclic group is optionally further substituted by one or more groups selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy.

[0053] In another preferred embodiment of the present invention, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein:

[0054] R 1 Select from -OR a ;

[0055] R a Selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, especially cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or 5-8 membered heterocyclyl, especially oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, wherein the C1-C6 alkyl, C3-C6 cycloalkyl, 5-8 membered heterocyclyl is optionally further substituted by one or more groups selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy.

[0056] In another preferred embodiment of the present invention, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein:

[0057] R 1 Selected from -P(O)R a R b ;

[0058] R a Selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, in particular cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or 5-8 membered heterocyclyl, in particular oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, wherein the C1-C6 alkyl, C3-C6 cycloalkyl, 5-8 membered heterocyclyl is optionally further substituted by one or more groups selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy;

[0059] R b Selected from hydrogen or C1-C6 alkyl;

[0060] or R a and R b Together with the atoms to which they are attached, they form a 5- to 8-membered heterocyclic group, in particular a phospholyl group; the heterocyclic group is optionally further substituted by one or more groups selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy.

[0061] In another preferred embodiment of the present invention, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein:

[0062] R 2 Selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C7 cycloalkyl, 5 to 7 membered heterocyclyl; preferably C1-C6 alkyl; wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl is optionally further substituted by one or more groups selected from halogen, amino, nitro, cyano, oxo, hydroxyl, thiol, carboxyl, ester, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl.

[0063] In another preferred embodiment of the present invention, the compound represented by the general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salt thereof, wherein:

[0064] L is selected from -C(R 4 R 5 )-;

[0065] R 4 and R 5 Each is independently selected from hydrogen, C1-C6 alkyl, and C1-C6 alkoxy.

[0066] Typical compounds of the present invention include, but are not limited to:

[0067]

[0068]

[0069] Its meso form, racemate, enantiomer, diastereomer, or mixture form, or its pharmaceutically acceptable salt.

[0070] The present invention further provides a method for preparing the compound represented by general formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, its prodrug or pharmaceutically acceptable salt thereof, which comprises the following steps:

[0071]

[0072] In the presence of a condensing agent, compound Ig and Ih are subjected to a condensation reaction under alkaline conditions to obtain a compound of formula (I), wherein the alkaline condition is preferably DIPEA and the condensing agent is preferably HATU;

[0073] Among them, W1 , W 2 , W 3 , A 1 , A 2 , A 3 , A 4 , A 5 , R 1 , R 2 , R 3 , L, and n are as defined in the general formula (I).

[0074] Another aspect of the present invention provides a pharmaceutical composition, which contains the compound represented by the general formula (I) according to the present invention or its racemate, racemate, enantiomer, diastereomer, or mixture thereof, its prodrug or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0075] The present invention further provides use of the compound represented by general formula (I) according to the present invention or its racemate, racemate, enantiomer, diastereomer, or mixture thereof, its prodrug or pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, in the preparation of a P2X3 antagonist.

[0076] The present invention further provides the use of the compound represented by the general formula (I) according to the present invention or its racemate, racemate, enantiomer, diastereomer, or mixture thereof, its prodrug or pharmaceutically acceptable salt, or a pharmaceutical composition containing the same, in the preparation of a medicament for preventing and / or treating diseases related to P2X3 activity.

[0077] The present invention further provides a compound represented by the general formula (I) according to the present invention or its racemate, racemate, enantiomer, diastereomer, or mixture thereof, a prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, and its use as a P2X3 antagonist.

[0078] The present invention further provides a compound represented by the general formula (I) according to the present invention or its racemate, racemate, enantiomer, diastereomer, or mixture thereof, a prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, and its use as a drug for preventing and / or treating diseases related to P2X3 activity.

[0079] The present invention further provides a method for preventing and / or treating diseases associated with P2X3 activity, comprising administering to a subject in need thereof a preventive or therapeutically effective amount of a compound of formula (I) according to the present invention or its mesomorph, racemate, enantiomer, diastereoisomer, or mixture thereof, a prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same.

[0080] In a preferred embodiment of the present invention, the diseases associated with P2X3 activity according to the present invention can be: respiratory diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchospasm, pulmonary fibrosis, acute cough, chronic cough including chronic idiopathic and chronic refractory cough, urogenital system, gastrointestinal tract, respiratory and pain related diseases, gynecological diseases including dysmenorrhea (primary and secondary dysmenorrhea), dyspareunia, dysuria or orchitis, endometriosis and adenomyosis, endometriosis. associated pain, symptoms associated with endometriosis, pelvic hypersensitivity, urinary tract disease states associated with bladder outlet obstruction, urinary incontinence symptoms such as decreased bladder capacity, increased frequency of urination, urge incontinence, stress incontinence or overactive bladder, benign prostatic hypertrophy, prostatic hyperplasia, prostatitis, detrusor hyperreflexia, overactive bladder and symptoms associated with overactive bladder, wherein the symptoms are particularly frequent urination, nocturia, urgency or urge incontinence, pelvic hypersensitivity; urethritis, prostatitis, prostatodynia, Cystitis, in particular interstitial cystitis, idiopathic hypersensitive bladder, epilepsy, partial and generalized seizures, gastrointestinal disorders including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), biliary colic and other biliary diseases, renal colic, diarrhea-predominant IBS, gastroesophageal reflux, gastrointestinal dilatation, Crohn's disease, neurodegenerative diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's disease, cerebral ischemia and traumatic brain injury, myocardial infarction, lipid disorders, pain-related diseases or conditions selected from hyperalgesia, allodynia Pain, functional bowel disorders, gout, arthritis (such as osteoarthritis, rheumatoid arthritis and ankylosing spondylitis), burning mouth syndrome, burns, migraine or cluster headaches, nerve damage, post-traumatic injury (including fractures and sports injuries), neuritis, neuralgia, poisoning, ischemic injury, interstitial cystitis, cancer, trigeminal neuralgia, small fiber neuropathy, diabetic neuropathy, chronic arthritis and related neuropathies, neuropathy caused by HIV and HIV treatment, pruritus, impaired wound healing and bone diseases such as joint degeneration, etc.

[0081] According to the conventional method in the field of the present invention, the compound represented by the general formula (I) of the present invention can form a pharmaceutically acceptable acid addition salt with an acid. The acid includes inorganic acids and organic acids, and is particularly preferably hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalene disulfonic acid, acetic acid, propionic acid, lactic acid, trifluoroacetic acid, maleic acid, citric acid, fumaric acid, oxalic acid, tartaric acid, benzoic acid, etc.

[0082] According to the conventional method in the field to which the present invention belongs, the compound represented by the general formula (I) of the present invention can form a pharmaceutically acceptable basic addition salt with a base. The base includes an inorganic base and an organic base, and the acceptable organic base includes diethanolamine, ethanolamine, N-methylglucamine, triethanolamine, tromethamine, etc., and the acceptable inorganic base includes aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate and sodium hydroxide, etc.

[0083] In addition, the present invention also includes prodrugs of the compounds of the general formula (I) of the present invention. The prodrugs of the present invention are derivatives of the compounds of the general formula (I), which may have weak activity or even no activity themselves, but after administration, they are converted into corresponding biologically active forms under physiological conditions (e.g., by metabolism, solvolysis or other means).

[0084] The pharmaceutical composition containing the active ingredient may be in a form suitable for oral administration, such as tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Oral compositions may be prepared according to any method known in the art for preparing pharmaceutical compositions, and such compositions may contain one or more ingredients selected from the following: sweeteners, flavoring agents, colorants and preservatives to provide pleasing and palatable pharmaceutical preparations. Tablets contain the active ingredient and non-toxic pharmaceutically acceptable excipients suitable for preparing tablets for mixing. These excipients may be inert excipients such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating agents and disintegrants such as microcrystalline cellulose, crosslinked sodium carboxymethyl cellulose, corn starch or alginic acid; binders such as starch, gelatin, polyvinyl pyrrolidone or gum arabic; and lubricants such as magnesium stearate, stearic acid or talc. These tablets may be uncoated or may be coated by known techniques which mask the taste of the drug or delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained release action over a longer period of time. For example, water soluble taste masking materials such as hydroxypropylmethylcellulose or hydroxypropylcellulose, or time extending materials such as ethylcellulose, cellulose acetate butyrate may be used.

[0085] Oral preparations may also be provided in hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin, or in soft gelatin capsules wherein the active ingredient is mixed with a water-soluble carrier such as polyethylene glycol or an oily vehicle such as peanut oil, liquid paraffin or olive oil.

[0086] Aqueous suspensions contain the active substance and excipients suitable for preparing aqueous suspensions for mixing. Such excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone and gum arabic; dispersants or wetting agents, which may be naturally occurring phosphatides such as lecithin, or condensation products of alkylene oxides with fatty acids, for example, polyoxyethylene stearate, or condensation products of ethylene oxide with long chain fatty alcohols, for example, heptadecaethyleneoxy cetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol, for example, polyethylene oxide sorbitan monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example, polyethylene oxide dehydrated sorbitan monooleate. The aqueous suspension may also contain one or more preservatives, for example ethylparaben or n-propylparaben, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, for example sucrose, saccharin or aspartame.

[0087] Oil suspensions can be prepared by suspending the active ingredient in a vegetable oil such as peanut oil, olive oil, sesame oil or coconut oil, or a mineral oil such as liquid paraffin. The oil suspension may contain a thickener such as beeswax, hard paraffin or cetyl alcohol. The above-mentioned sweeteners and flavoring agents may be added to provide a palatable preparation. These compositions may be preserved by adding an antioxidant such as butylated hydroxyanisole or alpha-tocopherol.

[0088] Dispersible powders and granules suitable for preparing aqueous suspensions can provide the active ingredient and a dispersant or wetting agent, a suspending agent or one or more preservatives for mixing by adding water. Suitable dispersants or wetting agents and suspending agents are as described above. Other excipients such as sweeteners, flavoring agents and coloring agents can also be added. These compositions can be preserved by adding antioxidants such as ascorbic acid.

[0089] The pharmaceutical composition of the present invention can also be in the form of an oil-in-water emulsion. The oil phase can be a vegetable oil such as olive oil or peanut oil, or a mineral oil such as liquid paraffin or a mixture thereof. Suitable emulsifiers can be naturally occurring phospholipids, such as soybean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of the partial esters and ethylene oxide, such as polyethylene oxide sorbitol monooleate. Emulsions can also contain sweeteners, flavoring agents, preservatives, and antioxidants. Syrups and elixirs prepared with sweeteners such as glycerol, propylene glycol, sorbitol, or sucrose can be used. Such preparations can also contain a demulcent, a preservative, a coloring agent, and an antioxidant.

[0090] The pharmaceutical composition of the present invention may be in the form of a sterile injectable aqueous solution. Acceptable vehicles and solvents that may be used are water, Ringer's solution and isotonic sodium chloride solution. The sterile injectable preparation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in an oil phase. For example, the active ingredient is dissolved in a mixture of soybean oil and lecithin. The oil solution is then added to a mixture of water and glycerol and processed to form a microemulsion. The injection or microemulsion may be injected into the patient's bloodstream by local mass injection. Alternatively, the solution and microemulsion may be preferably administered in a manner that maintains a constant circulating concentration of the compound of the present invention. To maintain this constant concentration, a continuous intravenous drug delivery device may be used.

[0091] The pharmaceutical composition of the present invention can be in the form of a sterile injection water or oil suspension for intramuscular and subcutaneous administration. The suspension can be prepared by known techniques with the above-mentioned suitable dispersants or wetting agents and suspending agents. The sterile injection preparation can also be a sterile injection solution or suspension prepared in a non-toxic parenteral acceptable diluent or solvent, such as a solution prepared in 1,3-butanediol. In addition, sterile fixed oil can be conveniently used as a solvent or suspension medium. For this purpose, any blended fixed oil including synthetic glycerol mono- or di-esters can be used. In addition, fatty acids such as oleic acid can also be used to prepare injections.

[0092] The compounds of the invention may be administered in the form of suppositories for rectal administration. These pharmaceutical compositions may be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid in the rectum and which will dissolve in the rectum to release the drug. Such materials include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, polyethylene glycols of various molecular weights and mixtures of fatty acid esters of polyethylene glycol.

[0093] It is well known to those skilled in the art that the dosage of a drug depends on a variety of factors, including but not limited to the following factors: the activity of the specific compound used, the patient's age, the patient's weight, the patient's health condition, the patient's behavior, the patient's diet, the administration time, the administration method, the excretion rate, the combination of drugs, etc. In addition, the best treatment method, such as the mode of treatment, the daily dosage of the general compound or the type of pharmaceutically acceptable salt can be verified according to traditional treatment plans.

[0094] The present invention may contain a compound represented by the general formula (I), and a pharmaceutically acceptable salt, hydrate or solvate thereof as an active ingredient, mixed with a pharmaceutically acceptable carrier or excipient to prepare a composition, and prepared into a clinically acceptable dosage form. The derivatives of the present invention may be used in combination with other active ingredients, as long as they do not produce other adverse effects, such as allergic reactions, etc. The compounds of the present invention may be used as the sole active ingredient, or in combination with other drugs for treating diseases associated with P2X3 activity. Combination therapy is achieved by administering the individual therapeutic components simultaneously, separately or sequentially.

[0095] Detailed description of the invention

[0096] Unless stated otherwise, the terms used in the specification and claims have the following meanings.

[0097] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms, and more preferably an alkyl group containing 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched chain isomers thereof. More preferred are lower alkyl groups containing 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. The alkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment. The substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate.

[0098] The term "alkenyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, such as vinyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, etc. The alkenyl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio.

[0099] The term "alkynyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond, such as ethynyl, propynyl, butynyl, etc. Alkynyl may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio.

[0100] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc.; polycyclic cycloalkyls include spirocyclic, fused and bridged cycloalkyls.

[0101] The term "spirocycloalkyl" refers to a polycyclic group that shares a carbon atom (called a spiral atom) between 5 to 20 monocyclic rings, which may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 yuan, more preferably 7 to 10 yuan. According to the number of spiral atoms shared between the rings, the spirocycloalkyl is divided into a single spiral cycloalkyl, a double spiral cycloalkyl or a multi-spirocycloalkyl, preferably a single spiral cycloalkyl and a double spiral cycloalkyl. More preferably, it is a 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan single spiral cycloalkyl. Non-limiting examples of spirocycloalkyl include:

[0102]

[0103] The term "condensed cycloalkyl" refers to a 5 to 20-membered, all-carbon polycyclic group in which each ring in the system shares a pair of adjacent carbon atoms with other rings in the system, wherein one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic condensed cycloalkyl, preferably a bicyclic or tricyclic, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic alkyl. Non-limiting examples of condensed cycloalkyls include:

[0104]

[0105] The term "bridged cycloalkyl" refers to a 5 to 20-membered, all-carbon polycyclic group in which any two rings share two carbon atoms that are not directly connected, which may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 members, and more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, preferably a bicyclic, tricyclic or tetracyclic, and more preferably a bicyclic or tricyclic. Non-limiting examples of bridged cycloalkyl include:

[0106]

[0107] The cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring attached to the parent structure is a cycloalkyl, non-limiting examples of which include indanyl, tetrahydronaphthyl, benzocycloheptanyl, etc. The cycloalkyl may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate.

[0108] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen or S(O). m(wherein m is an integer from 0 to 2) heteroatoms, but does not include -OO-, -OS- or -SS- ring parts, and the remaining ring atoms are carbon. Preferably, it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; most preferably, it contains 3 to 8 ring atoms, of which 1 to 3 are heteroatoms; most preferably, it contains 5 to 7 ring atoms, of which 1 to 2 or 1 to 3 are heteroatoms. Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, pyranyl, etc., preferably 1, 2, 5-oxadiazolyl, pyranyl or morpholinyl. Polycyclic heterocyclic groups include spirocyclic, fused ring and bridged heterocyclic groups.

[0109] The term "spiro heterocyclyl" refers to a polycyclic heterocyclic group in which the monocyclic rings of 5 to 20 members share one atom (called a spiro atom), wherein one or more of the ring atoms is selected from nitrogen, oxygen or S(O) m (wherein m is an integer 0 to 2) heteroatom, and the remaining ring atoms are carbon. It may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 yuan, more preferably 7 to 10 yuan. According to the number of shared spiral atoms between rings, the spiral heterocyclic group is divided into a single spiral heterocyclic group, a double spiral heterocyclic group or a multi-spiro heterocyclic group, preferably a single spiral heterocyclic group and a double spiral heterocyclic group. More preferably, it is a 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan single spiral heterocyclic group. Non-limiting examples of spiral heterocyclic groups include:

[0110]

[0111] The term "fused heterocyclyl" refers to a polycyclic heterocyclic group of 5 to 20 members, each ring in the system shares a pair of adjacent atoms with other rings in the system, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron system, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) m (wherein m is an integer from 0 to 2) heteroatoms, and the remaining ring atoms are carbon. Preferably 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic group, preferably a bicyclic or tricyclic, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic group. Non-limiting examples of fused heterocyclic groups include:

[0112]

[0113] The term "bridged heterocyclyl" refers to a 5- to 14-membered polycyclic heterocyclic group in which any two rings share two atoms that are not directly connected, which may contain one or more double bonds, but none of the rings has a completely conjugated π-electron system, and one or more of the ring atoms is selected from nitrogen, oxygen or S(O)m (wherein m is an integer from 0 to 2) heteroatoms, and the remaining ring atoms are carbon. Preferably, it is 6 to 14 members, and more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic, and more preferably bicyclic or tricyclic. Non-limiting examples of bridged heterocyclic groups include:

[0114]

[0115] The heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring attached to the parent structure is a heterocyclyl, non-limiting examples of which include:

[0116] wait.

[0117] The heterocyclyl group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate.

[0118] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., rings that share adjacent pairs of carbon atoms) group having a conjugated π electron system, preferably 6- to 10-membered, such as phenyl and naphthyl. More preferably phenyl. The aryl ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is an aryl ring, non-limiting examples of which include:

[0119]

[0120] The aryl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.

[0121] The term "heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen. The heteroaryl group is preferably 5 to 10 members, containing 1 to 3 heteroatoms; more preferably 5 or 6 members, containing 1 to 2 heteroatoms; preferably, for example, imidazolyl, furanyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, tetrazolyl, pyridyl, pyrimidyl, thiadiazole, pyrazinyl, etc., preferably imidazolyl, thiazolyl, pyrazolyl or pyrimidyl, thiazolyl; more preferably pyrazolyl or thiazolyl. The heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, non-limiting examples of which include:

[0122]

[0123] The heteroaryl group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.

[0124] The term "alkoxy" refers to-O-(alkyl) and-O-(unsubstituted cycloalkyl), wherein the definition of alkyl is as described above. The non-limiting examples of alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy. Alkoxy can be optionally substituted or unsubstituted, and when substituted, substituents are preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, sulfhydryl, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.

[0125] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.

[0126] The term "haloalkoxy" refers to an alkoxy group substituted with one or more halogens, wherein alkoxy is as defined above.

[0127] The term "hydroxyalkyl" refers to an alkyl group substituted with a hydroxy group, wherein alkyl is as defined above.

[0128] The term "hydroxy" refers to an -OH group.

[0129] The term "halogen" refers to fluorine, chlorine, bromine or iodine.

[0130] The term "amino" refers to -NH2.

[0131] The term "cyano" refers to -CN.

[0132] The term "nitro" refers to -NO2.

[0133] The term "oxo" refers to =0.

[0134] The term "carboxy" refers to -C(O)OH.

[0135] The term "thiol" refers to -SH.

[0136] The term "ester group" refers to -C(O)O(alkyl) or -C(O)O(cycloalkyl), wherein alkyl and cycloalkyl are as defined above.

[0137] The term "acyl" refers to a compound containing a -C(O)R group, wherein R is alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.

[0138] The term "sulfonic acid" refers to -S(O)2OH.

[0139] The term "sulfonate" refers to -S(O)2O(alkyl) or -S(O)2O(cycloalkyl), wherein alkyl and cycloalkyl are as defined above.

[0140] The term "sulfonyl" refers to a compound having a -S(O)2R group, wherein R is alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl.

[0141] The term "aminoacyl" refers to -C(O)-NRR', wherein R, R' are each independently hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl.

[0142] The term "aminosulfonyl" or "sulfonylamino" refers to -S(O)2-NRR', wherein R, R' are each independently hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl.

[0143] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may but need not be present, and the description includes instances where the heterocyclic group is substituted with an alkyl group and instances where the heterocyclic group is not substituted with an alkyl group.

[0144] "Substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms in the group are replaced independently of each other by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and the skilled person can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, amino or hydroxy groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (e.g. olefinic) bonds.

[0145] "Pharmaceutical composition" means a mixture containing one or more compounds described herein or their physiologically / pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.

[0146] "Pharmaceutically acceptable salts" refer to salts of the compounds of the present invention, which are safe and effective when used in mammals and have the desired biological activity.

[0147] Synthesis method of the compound of the present invention

[0148] In order to achieve the purpose of the present invention, the present invention adopts the following technical scheme.

[0149] The compound represented by the general formula (I) of the present invention or its racemate, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt can be prepared by the following scheme, and the specific preparation method is as follows.

[0150] (1) Scheme 1: When R 1 For-NR a R b When, according to the method of Scheme 1, compound Ia is used as the starting material to obtain the compound of general formula (I).

[0151]

[0152] Solution 1

[0153] Synthesis of Scheme 1:

[0154] Step 1: Compound Ia is reacted with R under acidic conditions and in the presence of a reducing agent. a (O) to obtain compound Ib, wherein the acidic reagent is preferably acetic acid and the reducing agent is preferably sodium cyanoborohydride;

[0155] Step 2: Under alkaline conditions, compound Ib is reacted with R b I to obtain compound Ic, wherein the alkaline reagent is preferably NaH;

[0156] Step 3: reacting compound Ic with bis(pinacol)boronic acid ester under high temperature, alkalinity and a catalyst to obtain compound Id, wherein the high temperature condition is preferably 100° C., the alkaline agent is preferably potassium acetate, and the catalyst is preferably Pd(dppf)Cl2 catalyst;

[0157] Step 4: reacting compound Id with compound Ie in the presence of high temperature, alkalinity and a catalyst to obtain compound If, wherein the high temperature condition is preferably 90° C., the alkaline agent is preferably potassium carbonate, and the catalyst is preferably Pd(dppf)Cl2 catalyst;

[0158] Step 5: Under alkaline conditions, hydrolyzing compound If to obtain compound Ig, wherein the alkaline agent is preferably lithium hydroxide;

[0159] Step 6: In the presence of a condensing agent, compound Ig is subjected to a condensation reaction with Ih under alkaline conditions to obtain a compound of formula (I), wherein the alkaline condition is preferably DIPEA and the condensing agent is preferably HATU.

[0160] (2) Scheme 2: When R 1 SO2R a When, according to the method of Scheme 2, compound Ii is used as the starting material to obtain the compound of general formula (I).

[0161]

[0162] Solution 2

[0163] Synthesis of Scheme 2:

[0164] Step 1: reacting compound Ii with (4-methoxyphenyl)methyl mercaptan in the presence of high temperature, alkalinity and a catalyst to obtain compound Ij, wherein the high temperature condition is preferably 100° C., the alkaline reagent is preferably DIPEA, and the catalyst is preferably Pd2(dba)3 and Xantphos;

[0165] Step 2: Under high temperature, alkalinity and the presence of a catalyst, compound Ij is reacted with bis-boronic acid pinacol ester to obtain compound Ik, wherein the high temperature condition is preferably 100° C., the alkaline agent is preferably potassium acetate, and the catalyst is preferably Pd(dppf)Cl2;

[0166] Step 3: Under high temperature, alkalinity and a catalyst, compound Ik is reacted with compound Ie to obtain compound Il, wherein the high temperature condition is preferably 90° C., the alkaline agent is preferably potassium carbonate, and the catalyst is preferably Pd(dppf)Cl2;

[0167] Step 4: reacting compound Il at low temperature and in the presence of an oxidant to obtain compound Im, wherein the low temperature condition is preferably -15°C, and the oxidant is preferably 1,3-dichloro-5,5-dimethylhydantoin (DCDMH);

[0168] Step 5: Under alkaline conditions, compound Im is reacted with HR a The reaction yields compound In, wherein the alkaline agent is preferably sodium carbonate;

[0169] Step 6: Under alkaline conditions, hydrolyze compound In to obtain compound Io, wherein the alkaline agent is preferably lithium hydroxide;

[0170] Step 7: In the presence of a condensing agent, compound Io is subjected to a condensation reaction with compound Ih under alkaline conditions to obtain a compound of formula (I), wherein the alkaline condition is preferably DIPEA and the condensing agent is preferably HATU.

[0171] (3) Scheme 3: When R 1 -S(O)2NR a R b When, according to the method of Scheme 3, compound Im is used as the starting material to obtain the compound of general formula (I).

[0172]

[0173] Solution 3

[0174] Synthesis of Scheme 3:

[0175] Step 1: Under alkaline conditions, compound Im is reacted with HNR a R b The reaction yields compound Ip, wherein the alkaline agent is preferably sodium carbonate;

[0176] Step 2: Under alkaline conditions, hydrolyzing compound Ip to obtain compound Iq, wherein the alkaline agent is preferably lithium hydroxide;

[0177] Step 3: In the presence of a condensing agent, compound Iq is subjected to a condensation reaction with Ih under alkaline conditions to obtain a compound of formula (I), wherein the alkaline condition is preferably DIPEA and the condensing agent is preferably HATU.

[0178] (4) Scheme 4: When R 1 -P(O)R a R b When, according to the method of Scheme 4, compound Ir is used as the starting material to obtain the compound of general formula (I).

[0179]

[0180] Solution 4

[0181] Synthesis of Scheme 4:

[0182] Step 1: Compound Ir is reacted with HP(O)R a R b The reaction yields compound Is, wherein the high temperature condition is preferably 65° C., the alkaline reagent is preferably potassium phosphate, and the catalyst is preferably Pd(OAc)2 and Xantphos;

[0183] Step 2: Under high temperature, alkalinity and the presence of a catalyst, compound Is is reacted with bis(pinacol)boronic acid to obtain compound It, wherein the high temperature condition is preferably 100° C., the alkaline agent is preferably potassium acetate, and the catalyst is preferably Pd(dppf)Cl2;

[0184] Step 3: Under high temperature, alkalinity and a catalyst, react compound It with Ie to obtain compound Iu, wherein the high temperature condition is preferably 90° C., the alkaline agent is preferably potassium carbonate, and the catalyst is preferably Pd(dppf)Cl2;

[0185] Step 4: Under alkaline conditions, hydrolyze compound Iu to obtain compound Iv, wherein the alkaline agent is preferably lithium hydroxide;

[0186] Step 5: In the presence of a condensing agent, compound Iv and Ih are subjected to a condensation reaction under alkaline conditions to obtain a compound of formula (I), wherein the alkaline condition is preferably DIPEA and the condensing agent is preferably HATU.

[0187] Among them, W 1 , W 2 , W 3 , A 1 , A 2 , A 3 , A 4 , A 5 , R 1 , R 2 , R 3 , L are as defined in the general formula (I). DETAILED DESCRIPTION

[0188] The present invention is further described below in conjunction with examples, but these examples are not intended to limit the scope of the present invention.

[0189] The structures of the compounds were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). -6 The unit of (ppm) is given. NMR measurements were performed using a Bruker dps300 nuclear magnetic spectrometer, with deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD) as the measuring solvent, and tetramethylsilane (TMS) as the internal standard.

[0190] MS was measured using a 1100 Series LC / MSD Trap (ESI) mass spectrometer (manufacturer: Agilent).

[0191] GC-MS measurement was performed using GCMS-QP2010 SE.

[0192] The preparative liquid phase was performed using LC3000 high performance liquid chromatograph and LC6000 high performance liquid chromatograph (manufacturer: Chuangxin Tongheng), and the chromatographic column was Daisogel C18 10 μm 60A (20 mm×250 mm).

[0193] For HPLC measurement, Shimadzu LC-20AD high pressure liquid chromatograph (Agilent TC-C18 250×4.6 mm 5 μm column) and Shimadzu LC-2010AHT high pressure liquid chromatograph (Phenomenex C18 250×4.6 mm 5 μm column) were used.

[0194] The thin layer chromatography silica gel plate used was Qingdao Ocean Chemical GF254 silica gel plate. The silica gel plate used in thin layer chromatography (TLC) had a specification of 0.15 mm to 0.2 mm, and the specification used for thin layer chromatography separation and purification products was 0.4 mm to 0.5 mm.

[0195] Column chromatography generally uses Qingdao Marine Silica Gel 100-200 mesh and 200-300 mesh silica gel as the carrier.

[0196] The known starting materials of the present invention can be synthesized by methods known in the art, or can be purchased from online shopping malls, Beijing Coupling, Sigma, Bailingwei, Yishiming, Shanghai Shuya, Inokai, Nanjing Yaoshi, Anaiji Chemical and other companies.

[0197] Unless otherwise specified in the examples, the reactions can be carried out under an argon atmosphere or a nitrogen atmosphere.

[0198] Argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a capacity of about 1L.

[0199] A CEM Discover SP microwave reactor was used for the microwave reaction.

[0200] Unless otherwise specified in the examples, the solution refers to an aqueous solution.

[0201] Unless otherwise specified in the examples, the reaction temperature is room temperature, 20°C to 30°C.

[0202] The reaction progress in the embodiment is monitored by thin layer chromatography (TLC), and the developing solvent systems used in the reaction are: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, C: petroleum ether and ethyl acetate system, D: acetone, and the volume ratio of the solvent is adjusted according to the polarity of the compound.

[0203] The eluent system of column chromatography and the developing solvent system of thin layer chromatography used for purifying compounds include: A: dichloromethane and methanol system, B: petroleum ether, ethyl acetate and dichloromethane system, C: petroleum ether and ethyl acetate system. The volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of alkaline or acidic reagents such as triethylamine and acetic acid can also be added for adjustment.

[0204] Unless otherwise defined, all professional and scientific terms used herein have the same meaning as those familiar to those skilled in the art. In addition, any method and material similar or equivalent to the described content can be applied to the method of the present invention.

[0205] Example

[0206] Example 1: Preparation of (R)-3-(methyl(oxetane-3-yl)amino)-5-(5-methylthiazol-2-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide (1)

[0207]

[0208] Step 1: Synthesis of methyl 3-bromo-5-(oxetane-3-ylamino)benzoate (1b)

[0209] 3-amino-5-bromobenzoic acid methyl ester (2.00g, 8.69mmol), oxetane-3-one (1.25g, 17.38mmol), acetic acid (1.58g, 26.07mmol), anhydrous ethanol (30mL) were added to the reaction bottle, heated to 60°C and stirred for 5 hours, then sodium cyanoborohydride (1.58g, 26.07mmol) was added, and stirring was continued at 60°C for 14 hours. After the reaction was completed, the reaction solution was filtered, saturated sodium bicarbonate solution was added to the filtrate to adjust the pH to 8-9, and then 50mL of dichloromethane and 50mL of water were added for extraction. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 2.34g of the title product as a light yellow solid with a yield of 93%.

[0210] Step 2: Synthesis of methyl 3-bromo-5-(methyl(oxetan-3-yl)amino)benzoate (1c)

[0211] 3-bromo-5-(oxetane-3-ylamino)benzoic acid methyl ester (2.34g, 8.18mmol) and DMF (30ml) were added to the reaction bottle, and then NaH (0.78g, 32.72mmol) was slowly added, stirred at room temperature for 1 hour, and then iodomethane (2.32g, 16.36mmol) was added, and the reaction was continued at room temperature for 14 hours. After the reaction was completed, 10mL of water was added dropwise to the reaction solution to quench. The reaction solution was concentrated under reduced pressure, and 60mL of dichloromethane and 60mL of water were added to extract. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 5: 1) to obtain 1.30g of the title product as a white solid, with a yield of 53%.

[0212] Step 3: Synthesis of methyl 3-(methyl(oxetane-3-yl)amino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (1d)

[0213] 3-Bromo-5-(methyl(oxetane-3-yl)amino)benzoic acid methyl ester (1.15g, 32.72mmol), BPD (bis-boronic acid pinacol ester) (1.46g, 5.75mmol), potassium acetate (0.75g, 7.66mmol), 1,4-dioxane (25ml), Pd(dppf)Cl2 (0.14g, 0.19mmol) were added to the reaction bottle, and the temperature was raised to 100°C and stirred for 20 hours under nitrogen protection. After the reaction was completed, the reaction solution was concentrated under reduced pressure, and the residue was extracted with 50mL of ethyl acetate and 50mL of water. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 5: 1) to obtain 0.96g of the title product as a white solid with a yield of 63%.

[0214] Step 4: Synthesis of methyl 3-(methyl(oxetan-3-yl)amino)-5-(5-methylthiazol-2-yl)benzoate (1e)

[0215] 3-(Methyl(oxetane-3-yl)amino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid methyl ester (0.96g, 2.76mmol), 2-bromo-5-methylthiazole (0.59g, 3.32mmol), potassium carbonate (0.92g, 6.65mmol), water (5mL), tetrahydrofuran (25mL), Pd(dppf)Cl2 (0.30g, 0.86mmol) were added to the reaction bottle, and the temperature was raised to 90°C and stirred for 16 hours under nitrogen protection. After the reaction was completed, the reaction solution was concentrated under reduced pressure, and the residue was extracted with 50mL of ethyl acetate and 50mL of water. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 5:1) to obtain 0.8 g of the title product as a light green liquid in a yield of 90%.

[0216] Step 5: Synthesis of 3-(methyl(oxetane-3-yl)amino)-5-(5-methylthiazol-2-yl)benzoic acid (1f)

[0217] 3-(Methyl(oxetane-3-yl)amino)-5-(5-methylthiazol-2-yl)benzoic acid methyl ester (0.70g, 2.20mmol), 1N lithium hydroxide solution (10mL), tetrahydrofuran (20mL), methanol (20mL) were added to the reaction flask and stirred at room temperature for 14 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure, 1N hydrochloric acid solution was added to adjust the pH to 3-4, and 50mL of ethyl acetate and 50mL of water were added for extraction. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane: methanol = 20: 1) to obtain 0.16g of the title product as a yellow solid with a yield of 24%.

[0218] Step 6: Synthesis of (R)-3-(methyl(oxetane-3-yl)amino)-5-(5-methylthiazol-2-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide (Compound 1)

[0219] 3-(Methyl(oxetane-3-yl)amino)-5-(5-methylthiazol-2-yl)benzoic acid (80 mg, 0.26 mmol), (R)-1-(2-(trifluoromethyl)pyrimidin-5-yl)ethan-1-amine (prepared according to document WO2010111059) (66 mg, 0.29 mmol), DIPEA (diisopropylethylamine) (136 mg, 1.05 mmol), HATU (2-(7-benzotriazole oxide)-N, N, N', N'-tetramethyluronium hexafluorophosphate) (140 g, 0.37 mmol), and DMF (10 mL) were added to the reaction flask and stirred at room temperature for 2 hours. After the reaction was completed, 30 mL of ethyl acetate and 30 mL of water were added for extraction. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative liquid chromatography (chromatographic column: Hedea ODS-2C18, 300 mm*250 mm, 10 μm; eluent: acetonitrile / water=0%-100%) to obtain 55 mg of the title product as a yellow solid in a yield of 44%.

[0220] LC-MS: m / z 478.41 [M+H] + .

[0221] 1 H NMR (300MHz, DMSO-d6) δ1.11(m, 3H), 1.61(m, 3H), 2.99(m, 3H), 4.63(m, 2H), 4.82(m , 2H), 4.87(m, 1H), 5.29(m, 1H), 7.23(m, 2H), 7.62(m, 1H), 7.70(m, 1H), 9.10(m, 3H).

[0222] Example 2: Preparation of (R)-3-(5-methylthiazol-2-yl)-5-(pyrrolidin-1-ylsulfonyl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide (2)

[0223]

[0224] Step 1: Synthesis of methyl 3-bromo-5-((4-methoxybenzyl)thio)benzoate (2b)

[0225] Methyl 3,5-dibromobenzoate (5.0 g, 17.0 mmol), (4-methoxyphenyl) methyl mercaptan (2.09 g, 13.6 mmol), Pd2(dba)3 (1.95 g, 3.4 mmol), Xantphos (4,5-bis(diphenylphosphine)-9,9-dimethylxanthene) (1.95 g, 3.4 mmol), dioxane (50 mL), DIPEA (4.4 g, 34 mmol) were added to a reaction flask and stirred at 100° C. for 16 hours under nitrogen protection. After the reaction was completed, the reaction solution was filtered and the filtrate was concentrated to dryness. The residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 2:1) to obtain 4.16 g of the title product as a yellow oil, with a yield of 66.8%.

[0226] Step 2: Synthesis of methyl 3-((4-methoxybenzyl)thio)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (2c)

[0227] Add methyl 3-bromo-5-((4-methoxybenzyl)thio)benzoate (4.16 g, 11.4 mmol), BPD (4.33 g, 17.0 mmol), potassium acetate (2.23 g, 22.8 mmol), Pd(dppf)Cl2 (0.42 g, 0.57 mmol), and DMF (40 mL) to a reaction flask and stir at 110° C. for 3 hours. After the reaction is completed, the reaction solution is filtered and the filtrate is concentrated to dryness. The residue is purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 2:1) to obtain 5.2 g of the title product as a yellow oil, with a yield of 110%.

[0228] Step 3: Synthesis of methyl 3-((4-methoxybenzyl)thio)-5-(5-methylthiazol-2-yl)benzoate (2d)

[0229] Methyl 3-((4-methoxybenzyl)thio)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (5.2 g, 12.47 mmol), 2-bromo-5-methylthiazole (2.66 g, 14.96 mmol), potassium carbonate (4.13 g, 29.93 mmol), Pd(dppf)Cl2 (1.37 g, 1.87 mmol), THF (200 mL), and water (30 mL) were added to a reaction flask and stirred at 90° C. for 16 hours under nitrogen protection. After the reaction was completed, the reaction solution was filtered, and 100 mL of ethyl acetate and 100 mL of water were added to the filtrate for extraction. The organic phase was washed once with water, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 3:1) to obtain 2.6 g of the title product as a yellow oil. Yield: 54.1%.

[0230] Step 4: Synthesis of methyl 3-(chlorosulfonyl)-5-(5-methylthiazol-2-yl)benzoate (2e)

[0231] Methyl 3-((4-methoxybenzyl)thio)-5-(5-methylthiazol-2-yl)benzoate (2.4 g, 6.2 mmol), acetonitrile (80 mL), water (2 mL), and acetic acid (1 mL) were added to a reaction flask, cooled to -15°C, and DCDMH (1,3-dichloro-5,5-dimethylhydantoin) (1.7 g, 8.7 mmol) was added to the reaction flask, and stirred at -15°C for 4 hours. After the reaction was completed, 80 mL of dichloromethane and 80 mL of water were added to the reaction solution for extraction, the organic phase was washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 1:1) to obtain 1.46 g of the title product as a white solid, with a yield of 70.8%.

[0232] Step 5: Synthesis of methyl 3-(5-methylthiazol-2-yl)-5-(pyrrolidin-1-ylsulfonyl)benzoate (2f)

[0233] Methyl 3-(chlorosulfonyl)-5-(5-methylthiazol-2-yl)benzoate (1.3 g, 3.92 mmol), THF (20 mL), water (20 mL), sodium carbonate (1.25 g, 11.78 mmol), and tetrahydropyrrole (0.84 g, 11.78 mmol) were added to a reaction flask and stirred at room temperature for 16 hours. After the reaction was completed, the reaction solution was filtered, the filter cake was washed twice with water, and the filter cake was dried to obtain 1.4 g of the title product as a white solid, with a yield of 97.4%.

[0234] Step 6: Synthesis of 3-(5-methylthiazol-2-yl)-5-(pyrrolidin-1-ylsulfonyl)benzoic acid (2 g)

[0235] Methyl 3-(5-methylthiazol-2-yl)-5-(pyrrolidin-1-ylsulfonyl)benzoate (1.4 g, 3.8 mmol), THF (20 mL), methanol (20 mL), and 1N lithium hydroxide (20 mL) were added to a reaction flask and stirred at room temperature for 16 hours. After the reaction, the reaction solution was adjusted to pH 3-4 with 1N hydrochloric acid, filtered, and the filter cake was washed twice with water and dried to obtain 1.3 g of the title product as a white solid, with a yield of 96.5%.

[0236] Step 7: Synthesis of (R)-3-(5-methylthiazol-2-yl)-5-(pyrrolidin-1-ylsulfonyl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide (Compound 2)

[0237] 3-(5-methylthiazol-2-yl)-5-(pyrrolidin-1-ylsulfonyl)benzoic acid (140 mg, 0.40 mmol), DMF (10 mL), HATU (213 mg, 0.56 mmol), DIPEA (206 mg, 1.60 mmol), (R)-1-(2-(trifluoromethyl)pyrimidin-5-yl)ethan-1-amine (100 mg, 0.44 mmol) were added to the reaction flask and stirred at room temperature for 16 hours. After the reaction was completed, the reaction solution was poured into 100 mL of ice water, stirred for 10 minutes, filtered, and the filter cake was purified by preparative liquid chromatography (chromatographic column: Hedea ODS-2C18, 300 mm*250 mm, 10 μm; eluent: 0%-100% acetonitrile: aqueous solution) to obtain 107 mg of the title product as a white solid, with a yield of 51.2%.

[0238] LC-MS: m / z 526.29 [M+H] + .

[0239] 1 H NMR (300MHz, DMSO-d6) δ 1.67 (m, 8H), 2.55 (m, 3H), 3.19 (m, 3H), 5.31 (m, 1H), 7.74 (m, 1H), 8.33 (m, 2H), 8.60 (m, 1H), 9.16 (s, 2H), 9.50 (m, 1H).

[0240] Example 3: Preparation of (R)-3-(5-methylthiazol-2-yl)-5-sulfamoyl-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide (3)

[0241]

[0242] The title compound 3 was prepared in the same manner as in Example 2, except that ammonia water was used instead of tetrahydropyrrole.

[0243] LC-MS: m / z 472.4 [M+H] + .

[0244] 1 H NMR (300MHz, DMSO-d6) δ1.63 (m, 3H), 2.50 (s, 3H), 5.34 (m, 1H), 7.60 (m, 2H), 7 .73(s, 1H), 8.35(s, 1H), 8.46(s, 1H), 8.53(s, 1H), 9.14(s, 2H), 9.47(m, 1H).

[0245] Example 4: Preparation of (R)-3-((4-methylpiperazin-1-yl)sulfonyl)-5-(5-methylthiazol-2-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide (4)

[0246]

[0247] The title compound 4 was prepared in the same manner as in Example 2, except that N-methylpiperazine was used instead of tetrahydropyrrole.

[0248] LC-MS: m / z 555.4 [M+H] + .

[0249] 1 H NMR (300MHz, DMSO-d6) δ1.73(m, 3H), 2.12(m, 3H), 2.36(m, 4H), 2.49(m, 3H), 2.06(m , 4H), 5.92(m, 1H), 7.74(m, 1H), 8.22(m, 2H), 8.01(m, 1H), 8.14(s, 2H), 9.04(m, 1H).

[0250] Example 5: Preparation of (R)-3-(N-cyclopropylsulfamoyl)-5-(5-methylthiazol-2-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide (5)

[0251]

[0252] The title compound 5 was prepared in the same manner as in Example 2, except that cyclopropylamine was used instead of tetrahydropyrrole.

[0253] LC-MS: m / z 512.4 [M+H] + .

[0254] 1 H NMR (300MHz, DMSO-d6) δ0.40(m, 2H), 0.50(m, 2H), 1.63(m, 3H), 2.21(m, 1H), 2.55(s, 3H), 5.34(m , 1H), 7.74(m, 1H), 8.18(s, 1H), 8.34(s, 1H), 8.43(s, 1H), 8.58(s, 1H), 9.15(s, 2H), 9.49(m, 1H).

[0255] Example 6: Preparation of (R)-3-(dimethylphosphonyl)-5-(5-methylthiazol-2-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide (6)

[0256]

[0257] Step 1: Synthesis of methyl 3-bromo-5-(dimethylphosphonyl)benzoate (6b)

[0258] Methyl 3-bromo-5-iodobenzoate (6a) (2.00 g, 5.87 mmol), dimethylphosphine oxide (0.69 g, 8.80 mmol), potassium phosphate (1.50 g, 7.04 mmol), 1,4-dioxane (15 mL), Xantphos (0.2 g, 0.35 mmol), Pd(OAc)2 (65 mg, 0.29 mmol) were added to a reaction flask, and the mixture was heated to 65°C and stirred for 2 hours under nitrogen protection. After the reaction was completed, the reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: dichloromethane: methanol = 20: 1) to obtain 0.8 g of the title product as an orange-yellow solid, with a yield of 47%.

[0259] Step 2: Synthesis of methyl 3-(dimethylphosphonyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (6c)

[0260] Methyl 3-bromo-5-(dimethylphosphonyl)benzoate (0.5 g, 1.72 mmol), BPD (0.87 g, 3.44 mmol), potassium acetate (0.5 g, 5.16 mmol), 1,4-dioxane (20 mL), and Pd(dppf)Cl2 (63 mg, 0.086 mmol) were added to a reaction flask, and the mixture was heated to 100° C. and stirred for 16 hours under nitrogen protection. After the reaction was completed, the mixture was filtered and the filtrate was concentrated under reduced pressure to obtain 1.3 g of the title product as a black solid crude product, which was directly used in the next step.

[0261] Step 3: Synthesis of methyl 3-(dimethylphosphonyl)-5-(5-methylthiazol-2-yl)benzoate (6d)

[0262] 3-(Dimethylphosphonyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid methyl ester (1.3g, 3.8mmol), 2-bromo-5-methylthiazole (0.18g, 1.02mmol), 1N potassium carbonate solution (5mL), tetrahydrofuran (20mL), Pd(dppf)Cl2 (75mg, 0.1mmol) were added to the reaction bottle, and the temperature was raised to 80°C and stirred for 14 hours under nitrogen protection. After the reaction was completed, the reaction solution was concentrated under reduced pressure, 50mL of ethyl acetate and 50mL of water were added to the residue for extraction, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: dichloromethane: methanol = 2:1) to obtain 0.30g of the title product as a black liquid with a yield of 25%.

[0263] Step 4: Synthesis of 3-(dimethylphosphonyl)-5-(5-methylthiazol-2-yl)benzoic acid (6e)

[0264] 3-(Dimethylphosphonyl)-5-(5-methylthiazol-2-yl)benzoic acid methyl ester (0.25g, 0.81mmol), 1N lithium hydroxide solution (3mL), tetrahydrofuran (5mL), methanol (5mL) were added to the reaction flask in sequence and stirred at room temperature for 1 hour. After the reaction was completed, 1N hydrochloric acid solution was added to the reaction solution to adjust the pH to 3-4 and filtered. The filter cake was washed with 20mL of water and dried to obtain 80mg of the title product as a yellow solid in a yield of 34%.

[0265] Step 5: Synthesis of (R)-3-(dimethylphosphonyl)-5-(5-methylthiazol-2-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide (Compound 6)

[0266] 3-(Dimethylphosphonyl)-5-(-methylthiazol-2-yl)benzoic acid (70 mg, 0.24 mmol), (R)-1-(2-(trifluoromethyl)pyrimidin-5-yl)ethan-1-amine (60 mg, 0.26 mmol), DIPEA (0.12 g, 0.96 mmol), HATU (0.13 g, 0.34 mmol), and DMF (10 mL) were added to a reaction flask and stirred at room temperature for 1 hour. After the reaction was completed, 50 mL of ethyl acetate and 50 mL of water were added to the reaction solution for extraction, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative liquid chromatography (chromatographic column: Hedea ODS-2 C18, 300 mm*250 mm, 10 μm; eluent: acetonitrile / water = 0%-100%) to obtain 39 mg of the title product as a white solid with a yield of 35%.

[0267] LC-MS: m / z 469.2 [M+H] + .

[0268] 1 H NMR (300MHz, DMSO-d6) δ1.63 (m, 3H), 1.74 (m, 6H), 2.51 (s, 3H), 5 34 (m, 1H), 7.70 (s, 1H), 8.28 (m, 1H), 8.36 (m, 1H), 8.47 (s, 1H), 9.14 (s, 2H), 9.34 (m, 1H).

[0269] Example 7: Preparation of (R)-3-(methyl(piperidin-4-yl)amino)-5-(5-methylthiazol-2-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide (7)

[0270]

[0271]

[0272] Step 1: Synthesis of (R)-3-(methyl(piperidin-4-yl)amino)-5-(5-methylthiazol-2-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide (Compound 7)

[0273] Preparation of (R)-tert-butyl 4-((3-(5-methylthiazol-2-yl)-5-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)carbamoyl)phenyl)aminomethyl-tert-butyl)piperidine-1-carboxylate (7a):

[0274] The intermediate 7a was prepared in the same manner as in Example 1, except that N-tert-butyloxycarbonyl-4-piperidone was used instead of oxetan-3-one.

[0275] (R)-4-((3-(5-methylthiazol-2-yl)-5-((1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)carbamoyl)phenyl)aminomethyl-tert-butyl)piperidine-1-carboxylate (400 mg, 0.66 mmol) and 2M dioxane hydrochloric acid solution (20 mL) were added to the reaction flask and stirred at room temperature for 3 hours. After the reaction was completed, saturated sodium bicarbonate aqueous solution was added to the reaction solution to adjust the pH value to 8-9, and the reaction solution was filtered. The filter cake was purified by preparative liquid chromatography (chromatographic column: Hedea ODS-2 C18, 300 mm*250 mm, 10 μm; eluent: acetonitrile / water = 0%-100%) to obtain 135 mg of the title product as a white solid with a yield of 40%.

[0276] LC-MS: m / z 505.2 [M+H] + .

[0277] 1 H NMR (300MHz, DMSO-d6) δ1.62(m, 3H), 1.68(m, 2H), 1.83(m, 2H), 2.50(s, 3H), 2.82(s, 3H), 2.88(m , 2H), 3.20(m, 2H), 2.97(m, 1H), 5.28(m, 1H), 7.33(m, 2H), 7.61(m, 2H), 9.12(s, 2H), 9.17(s, 1H).

[0278] Example 8: Preparation of (R)-3-(methyl(1-methylpiperidin-4-yl)amino)-5-(5-methylthiazol-2-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide (8)

[0279]

[0280] The title compound 8 was prepared in the same manner as in Example 1, except that N-methyl-4-piperidone was used instead of oxetan-3-one.

[0281] LC-MS: m / z 519.2 [M+H] + .

[0282] 1H NMR (300MHz, DMSO-d6) δ1.62 (m, 3H), 1.68 (m, 2H), 1.80 (m, 2H), 2.17 (m, 2H), 2.24 (s, 3H), 2.50 (s, 3H), 2 .82(s, 3H), 2.94(m, 2H), 3.70(m, 1H), 5.28(m, 1H), 7.28(m, 1H), 7.38(m, 1H), 7.60(m, 2H), 9.12(m, 3H).

[0283] Example 9: Preparation of (R)-3-(3-methyl-1H-pyrazol-1-yl)-5-(oxetane-3-yloxy)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide (9)

[0284]

[0285] Step 1: Synthesis of methyl 3-hydroxy-5-(3-methyl-1H-pyrazol-1-yl)benzoate (9b)

[0286] Add 3-bromo-5-hydroxybenzoic acid methyl ester (5.58g, 24mmol), 3-methyl-1H-pyrazole (2.98g, 36mmol), K2CO3 (6.62g, 48mmol), DMSO (60mL), CuI (2.28g, 12mmol), L-proline (2.76g, 24mmol) to the reaction flask and stir at 120°C for 16 hours. After the reaction, adjust the pH of the reaction solution to 4-5 with 1N hydrochloric acid, add 200mL of water, and extract with 200mL of ethyl acetate. Wash the organic phase three times with water, dry it with anhydrous sodium sulfate, filter it, and concentrate the filtrate under reduced pressure. The residue is purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 2:1) to obtain 0.64g of the title product as a yellow solid, with a yield of 10.7%.

[0287] Step 2: Synthesis of methyl 3-(3-methyl-1H-pyrazol-1-yl)-5-(oxetan-3-yloxy)benzoate (9c)

[0288] 3-Hydroxy-5-(3-methyl-1H-pyrazol-1-yl)benzoic acid methyl ester (0.64g, 2.7mmol), oxetane-3-yl 4-methylbenzenesulfonate (0.94g, 4.1mmol), cesium carbonate (1.34g, 4.1mmol), DMF (10mL) were added to the reaction flask and stirred at 110°C for 16 hours. After the reaction was completed, 50mL of ethyl acetate and 50mL of water were added to the reaction solution for extraction. The organic phase was washed twice with water, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 0.5g of the title product as a yellow oil with a yield of 62.9%.

[0289] Step 3: Synthesis of 3-(3-methyl-1H-pyrazol-1-yl)-5-(oxetan-3-yloxy)benzoic acid (9d)

[0290] Add 3-(3-methyl-1H-pyrazol-1-yl)-5-(oxetane-3-yloxy)benzoic acid methyl ester (0.5 g, 1.9 mmol), THF (6 mL), methanol (6 mL), and 1N lithium hydroxide (6 mL) to a reaction flask and stir at room temperature for 16 hours. After the reaction is completed, adjust the pH of the reaction solution to 3-4 with 1N hydrochloric acid, add 20 mL of water and 20 mL of ethyl acetate for extraction. The organic phase is washed with water and saturated brine in sequence, dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain 0.4 g of the title product as a yellow oil, with a yield of 75.1%.

[0291] Step 4: Synthesis of (R)-3-(3-methyl-1H-pyrazol-1-yl)-5-(oxetan-3-yloxy)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide (Compound 9)

[0292] 3-(3-methyl-1H-pyrazol-1-yl)-5-(oxetane-3-yloxy)benzoic acid (220 mg, 0.80 mmol), DMF (10 mL), HATU (426 mg, 1.12 mmol), DIPEA (413 mg, 3.20 mmol), (R)-1-(2-(trifluoromethyl)pyrimidin-5-yl)ethan-1-amine (201 mg, 0.88 mmol) were added to the reaction flask and stirred at room temperature for 16 hours. After the reaction was completed, 20 mL of ethyl acetate and 20 mL of water were added to the reaction solution for extraction, and the organic phase was washed twice with water, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative liquid chromatography (chromatographic column: Hedea ODS-2 C18, 300 mm*250 mm, 10 μm; eluent: 0%-100% acetonitrile:water solution) to give 99 mg of the title product as a white solid, yield: 27.6%.

[0293] LC-MS: m / z 448.16 [M+H] + .

[0294] 1H NMR (300MHz, DMSO-d6) δ1.61 (m, 3H), 2.28 (m, 3H), 4.57 (m, 2H), 4.96 (m, 2H), 5.28 (m, 1H), 5 .45 (m, 1H), 6.36 (m, 1H), 7.14 (m, 1H), 7.35 (m, 1H), 7.90 (s, 1H), 8.46 (s, 1H), 9.10 (m, 3H).

[0295] Example 10: Preparation of (R)-3-(((4,4-difluoropiperidin-1-yl)sulfonyl)-5-(5-methylthiazol-2-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide

[0296]

[0297] The title compound 10 was prepared in the same manner as in Example 2, except that 4,4-difluoropiperidine was used instead of tetrahydropyrrole.

[0298] LC-MS: m / z 576.35 [M+H] + .

[0299] 1 H NMR (300MHz, CDCl3) δ1.64 (d, J=7.2Hz, 3H), 2.09 (s, 4H), 2.55 (s, 3H), 3.17 (s, 4H), 5.35-5. 30 (m, 1H), 7.74 (s, 1H), 8.30-8.27 (m, 2H), 8.62 (s, 1H), 9.15 (s, 2H), 9.47 (d, J=6.6Hz, 1H).

[0300] Example 11: Preparation of (R)-3-((6-oxa-2-azaspiro[3.4]octyl-2-yl)sulfonyl)-5-(5-methylthiazol-2-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethylbenzamide

[0301]

[0302] The title compound 11 was prepared in the same manner as in Example 2, except that 6-oxa-2-azaspiro[3.4]octane was used instead of tetrahydropyrrole.

[0303] LC-MS: m / z 568.41 [M+H] + .

[0304] 1H NMR (300MHz, CDCl3) δ1.65 (d, J=7.1Hz, 3H), 1.87-1.84 (m, 2H), 2.55 (s, 3H), 3.49 (s, 2H), 3.58-3.54 (m, 2H), 3. 81-3.78 (m, 4H), 5.40 (s, 1H), 7.75 (s, 1H), 8.35-8.33 (m, 2H), 8.56 (s, 1H), 9.15 (s, 2H), 9.52 (d, J=6.9Hz, 1H).

[0305] Example 12: Preparation of (R)-3-(5-methylthiazol-2-yl)-5-(1-phosphinyl-1-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide

[0306]

[0307] Step 1: Synthesis of 1-cyclobutylphosphine oxide (12b):

[0308] At room temperature, under nitrogen atmosphere, magnesium chips (10.0 g, 417 mmol) were added to tetrahydrofuran (400 mL), stirred at room temperature for half an hour, and then 1,4-dibromobutane (43.0 g, 201 mmol) was added dropwise thereto, the reaction temperature was controlled to be lower than 30°C, and stirred at room temperature for 1.5 hours after the addition was complete. Then diethyl phosphonate (13.9 g, 100 mmol) was added dropwise thereto, the reaction temperature was controlled to be lower than 30°C, and the reaction was reacted at room temperature for 16 hours after the addition was complete. After the reaction was completed, quenched with 20% potassium carbonate aqueous solution (300 mL), filtered, and the filtrate was concentrated under reduced pressure. The residue was distilled under reduced pressure to obtain 530 mg of the title compound as a colorless oil, with a yield of 5.10%.

[0309] GC-MS: m / z 104.0 [M].

[0310] The remaining steps were the same as those of Example 6, except that 1-cyclobutylphosphine oxide (12b) was used instead of dimethylphosphine oxide to obtain the title compound 12.

[0311] LC-MS: m / z 494.62 [M+H] + .

[0312] 1 H NMR (400MHz, CDCl3) δ1.77 (d, 3H), 2.18-2.04 (m, 8H), 2.59 (s, 3H), 5.40 (s, 1H), 7.60 (s, 1H), 8.28-8.18 (m, 2H), 8.67 (s, 1H), 9.05 (s, 2H).

[0313] Biological evaluation of the compounds of the present invention

[0314] Test Example 1: Evaluation of the inhibitory activity of the compounds of the present invention on human P2X3 receptor

[0315] Fluorescence Image Plate Reader (FLIPR, Molecular Devices, 0296) was used to monitor the changes in intracellular calcium levels to evaluate the inhibitory activity of the compounds of the present invention on human P2X3 receptors.

[0316] Experimental procedure: HEK293-pCMV6-P2X3 cell line (Pharmaron, Clone #34) was revived and inoculated in complete medium (DMEM, high glucose (31053028, Gibco) + 10% fetal bovine serum (FBS) (Gibco, 10099141) + 4mM GlutaMAX (Gibco, 35050-061) + 1× penicillin-streptomycin, liquid (100×, Gibco, 15140-122) + 350 μg / ml geneticin (invitrogen, 10131-027), cultured in an incubator at 37°C, 5% CO2. When the cells were cultured to 70% to 90% confluence, the cells were digested with trypsin (Thermofisher, 12604021) and resuspended in cell seeding medium (DMEM, high glucose (31053028, Gibco) + 2% fetal bovine serum (FBS) (Gibco, 10099141) + 4mM GlutaMAX (Gibco, 35050-061)), 11000 cells / well / 25μL were inoculated into a 384-well cell culture plate (Corning, 3845), and cultured in an incubator at 37°C, 5% CO2 for 22 hours. Component A powder (FLIPR Calcium 6 Assay Kit, Molecular Devices, R8191) was diluted to 2× working concentration with assay buffer (1×HBSS (Gibco, 14025076) + 20mM HEPES (Gibco, 15630080)) and equilibrated to room temperature for use. The 384-well cell culture plate was equilibrated at room temperature for 10 minutes, the culture medium was removed, and 25μL of assay buffer and 25μL of 2×ComponentA, centrifuge at 200g for 3-5 seconds at room temperature, and stand at 37°C for 2 hours. Dilute α, β-MeATP (Sigma, M6517) to 2.1μM with experimental buffer, transfer 50μL to a 384-well plate, and place at room temperature for use. Take out the cell culture plate and stand at room temperature for 10 minutes, add the working solution of the test compound (the detection starting concentration is 10000nM, diluted 3 times with cell inoculation medium, so that the final DMSO concentration is 0.1%) to the corresponding experimental wells of the 384-well cell culture plate, and incubate at room temperature for 30 minutes. Use FLIPR Tetra (Molecular Devices, 0296) to add 10μL of diluted α, β-MeATP to the corresponding experimental wells to be tested, set the excitation wavelength to 470-495nm, and the emission wavelength to 515-575nm to detect the fluorescence value and collect data.

[0317] Calculation of compound IC using GraphPad four-parameter nonlinear fitting formula50 :

[0318]

[0319] X: log value of compound concentration; Y: ratio.

[0320] The inhibitory activity of the compounds of the present invention on P2X3 receptors is shown in Table 1 below.

[0321] Table 1. IC inhibition of P2X3 receptor by compounds of the present invention 50 value

[0322]

[0323]

[0324] A: IC 50 ≤100nM, B:100nM<IC 50 ≤200nM, C:200nM<IC 50

[0325] Conclusion: As described in Table 1 above, the compounds of the present invention exhibit in vitro P2X3 antagonist activity.

[0326] Test Example 2: Evaluation of the inhibitory activity of the compounds of the present invention on human P2X2 / 3 receptors

[0327] The FLIPR method was used to monitor the changes in intracellular calcium levels to evaluate the inhibitory activity of the compounds of the present invention on human P2X2 / 3 receptors.

[0328] Experimental procedure: HEK293 / hP2X2 / 3 cell line (Bioduro clone#164) was revived and inoculated into 384-well plates coated with 1X Matrigel (BD Bioscience, 354230) at 5 μL / well. Incubate at 37°C, 5% CO2 incubator for 30 minutes. Then treat the cells, remove the culture medium, wash once with PBS, digest the cells with 0.25% trypsin-EDTA (Invitrogen, 25200056), and adjust the cell density to 7.5X10 5 / mL. Add the diluted cells to a 384-well assay plate (Corning, 3709), 20 μL / well. Incubate the plate in a 37°C, 5% CO2 incubator overnight. Discard the cell culture medium in the 384-well assay plate and add 20 μL / well of freshly prepared Fluo-8 buffer (AAT Bioquest, 21080). Incubate in a 37°C, 5% CO2 incubator in the dark for 1 hour.

[0329] Prepare different concentrations of compounds and add 5 μL / well to a 384-well assay plate. Incubate in a 37°C, 5% CO2 incubator for 30 minutes. Prepare 6X EC80 of αβ-meATP (TOCRIS, 3209), add 5 μL / well to a 384-well assay plate using Flipr, and collect data.

[0330] The inhibitory activity of the compounds of the present invention on P2X2 / 3 receptors is shown in Table 2 below.

[0331] Compound <![CDATA[P2X2 / 3 IC 50 (nM)]]> Example 1 A Example 2 B Example 5 C Example 6 A Example 7 B Example 8 C

[0332] A: IC 50 >250nM, B:100n<IC 50 ≤250nM, C:IC 50 ≤100nM

[0333] Conclusion: As described in Table 2 above, the compounds of the present invention have poor inhibitory activity on P2X2 / 3 heterodimeric receptors.

[0334] Test Example 3: Pharmacokinetic properties of the compounds of the present invention

[0335] Animals: Wistar male rats, 180-220 g, 7-8 weeks old, purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., SPF grade, animal production license number: SCXK (Beijing) 2016-0011.

[0336] Experimental process: The oral dose of the compound of Example 6 and Example 12 is 3 mg / kg, and the blood sampling points are determined to be 8 minutes, 15 minutes, 30 minutes, 1 hour, 3 hours, 5 hours, 8 hours, 10 hours, 12 hours and 24 hours before and after oral administration. The animals are anesthetized by inhalation, and the anesthesia parameters are: flow rate: 1.0L / m, oxygen pressure: 0.1MPa, solubility: 4.5%, and anesthesia time: 3 minutes. After the animal is anesthetized, 0.5mL of blood is collected from the orbit, and the blood collection tube is pre-added with 10mg / mL heparin lithium and plasma volume ratio of 1:10 for anticoagulation. After mixing evenly, centrifuge at 3000rpm / min for 10 minutes, take the upper plasma, freeze it in a -20℃ refrigerator, and use it.

[0337] Take 50 μL of animal plasma sample and place it in a 1.5 ml EP tube, add 5 μL of internal standard working solution, and vortex for 60 seconds to mix thoroughly. After vortexing, add 0.2 mL of acetonitrile, vortex vigorously for 1 minute, and centrifuge at 16000 rpm for 10 minutes. Take 0.2 mL of supernatant, filter it with a 0.22 μm filter membrane, and add it to the injection vial for testing. Separate and measure under mass spectrometry conditions, and record the peak area of ​​each sample to be tested and the internal standard.

[0338] Data processing software was used to integrate the analyte and internal standard to obtain the peak area. The concentration of the analyte (x) was used as the horizontal coordinate, and the peak area ratio of the analyte to the internal standard (y) was used as the vertical coordinate. The weighted least square method (weight is 1 / x2) was used for regression operation. The linear regression equation obtained was the plasma calibration curve. DAS was used for statistical analysis. Various pharmacokinetic parameters and drug-time curves were obtained.

[0339] The pharmacokinetic properties of the compounds of Examples 6 and 12 of the present invention are shown in Table 3 below.

[0340] Example <![CDATA[AUC (0-t) (and / L*h)]]> <![CDATA[t 1 / 2z (h)]]> <![CDATA[T max (h)]]> <![CDATA[C max (and / L)]]> Example 6 >200 >5 >5 >20 Example 12 >200 >1 >1 >20

[0341] Test Example 4: Efficacy of the compounds of the present invention on histamine-citrate guinea pig acute cough model

[0342] Animals: Dunkin Hartley guinea pigs, male, 300-350 g, purchased from Beijing Jinmuyang Experimental Animal Breeding Co., Ltd., ordinary grade, animal production license number: SCXK (Beijing) 2015-0005.

[0343] Experimental process: The animals were divided into a model control group, a group receiving 3 mg / kg of the compound of Example 6, and a group receiving 30 mg / kg of the compound of Example 6. Each group was given the corresponding drug 30-60 minutes before stimulating the guinea pigs to cough. First, a 2 mg / mL histamine solution was ultrasonically atomized and inhaled into the sensitive guinea pigs for 1-2 minutes, and the guinea pigs were quickly taken out after coughing. After 5 minutes, a 2M citric acid solution was atomized and inhaled for 5 minutes to induce coughing; from the beginning of citric acid atomization, the cough latency and the number of coughs in the guinea pigs within 5 minutes were observed, and the antitussive effect of the compound of Example 6 on the guinea pig cough model was evaluated based on the cough latency and the number of coughs in the guinea pigs.

[0344] The therapeutic effects of the compounds of the present invention on the histamine-citrate guinea pig acute cough model are shown in Table 4 below.

[0345] Table 4. Changes in the latency period of cough in guinea pigs

[0346]

[0347] Note: *P<0.05vs model group; **P<0.01vs model group, T-test

[0348] Conclusion: The compound of Example 6 can effectively prolong the cough latency period of guinea pigs and significantly reduce the number of coughs, and is worthy of further development.

Claims

1. A compound represented by general formula (II) or a pharmaceutically acceptable salt thereof, in: Group is selected from thiazolyl; R 1 Selected from -NR a R b 、-S(O) m NR a R b 、-P(O)R a R b ; R 2 Selected from C 1-6 alkyl; R 3 The pyrimidinyl group is optionally further selected from halogen, C 1-6 Alkyl, C 1-6 One or more haloalkyl groups are substituted; L is selected from -C(R 4 R 5 )-; R 4 and R 5 are each independently selected from hydrogen, C 1-6 alkyl; R a Selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, 5-8 membered heterocyclyl, wherein the C1-C6 alkyl, C3-C6 cycloalkyl, 5-8 membered heterocyclyl is optionally further substituted by one or more groups selected from halogen, C1-C6 alkyl; R b is selected from hydrogen and C1-C6 alkyl; or R a and R b Together with the atoms to which they are attached, they form a 5- to 8-membered heterocyclic group, which is optionally further substituted with one or more groups selected from C1-C6 alkyl; m is 1 or 2; n is 1.

2. The compound represented by general formula (II) or a pharmaceutically acceptable salt thereof according to claim 1, wherein: R 1 Selected from -NR a R b ; R a Selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, or 5-8 membered heterocyclyl, wherein the C1-C6 alkyl, C3-C6 cycloalkyl, 5-8 membered heterocyclyl is optionally further substituted by one or more groups selected from halogen, C1-C6 alkyl; R b Selected from hydrogen or C1-C6 alkyl.

3. The compound represented by general formula (II) or a pharmaceutically acceptable salt thereof according to claim 2, wherein: The C3-C6 cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

4. The compound represented by general formula (II) or a pharmaceutically acceptable salt thereof according to claim 2, wherein: The 5- to 8-membered heterocyclic group is oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydropyrrolyl, piperidinyl, piperazinyl or morpholinyl.

5. The compound represented by general formula (II) or a pharmaceutically acceptable salt thereof according to claim 1, wherein: R 1 Selected from -NR a R b ; R a and R b Together with the nitrogen atom to which they are attached, they form a 5- to 8-membered heterocyclic group; the 5- to 8-membered heterocyclic group is optionally further substituted by one or more groups selected from C1-C6 alkyl.

6. The compound represented by general formula (II) or a pharmaceutically acceptable salt thereof according to claim 5, wherein: The 5- to 8-membered heterocyclic group is selected from tetrahydropyrrolyl, piperidinyl, piperazinyl or morpholinyl.

7. The compound represented by general formula (II) or a pharmaceutically acceptable salt thereof according to claim 1, wherein: R 1 Selected from -S(O)2NR a R b ; R a Selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, 5-8 membered heterocyclyl, wherein the C1-C6 alkyl, C3-C6 cycloalkyl, 5-8 membered heterocyclyl is optionally further substituted by one or more groups selected from halogen, C1-C6 alkyl; R b Selected from hydrogen or C1-C6 alkyl; Or, R a and R b Together with the nitrogen atom to which they are attached, they form a 5- to 8-membered heterocyclic group; the 5- to 8-membered heterocyclic group is optionally further substituted by one or more groups selected from C1-C6 alkyl.

8. The compound represented by general formula (II) or a pharmaceutically acceptable salt thereof according to claim 7, wherein: The C3-C6 cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

9. The compound represented by general formula (II) or a pharmaceutically acceptable salt thereof according to claim 7, wherein: R a The 5-8 membered heterocyclic group is selected from oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydropyrrolyl, piperidinyl, piperazinyl or morpholinyl; the 5-8 membered heterocyclic group is optionally further substituted by one or more groups selected from halogen, C1-C6 alkyl.

10. The compound represented by general formula (II) or a pharmaceutically acceptable salt thereof according to claim 7, wherein: R a and R b Together with the nitrogen atom to which they are attached, they form a 5- to 8-membered heterocyclic group selected from tetrahydropyrrolyl, piperidinyl, piperazinyl or morpholinyl; the 5- to 8-membered heterocyclic group is optionally further substituted by one or more groups selected from C1-C6 alkyl.

11. The compound represented by general formula (II) or a pharmaceutically acceptable salt thereof according to claim 1, wherein: R 1 Selected from -P(O)R a R b ; R a Selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, 5-8 membered heterocyclyl, wherein the C1-C6 alkyl, C3-C6 cycloalkyl, 5-8 membered heterocyclyl is optionally further substituted by one or more groups selected from halogen, C1-C6 alkyl; R b Selected from hydrogen or C1-C6 alkyl; or R a and R b Together with the atoms to which they are attached, they form a 5- to 8-membered heterocyclic group; the 5- to 8-membered heterocyclic group is optionally further substituted with one or more groups selected from C1-C6 alkyl.

12. The compound represented by general formula (II) or a pharmaceutically acceptable salt thereof according to claim 11, wherein: The C3-C6 cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

13. The compound represented by general formula (II) or a pharmaceutically acceptable salt thereof according to claim 11, wherein: R a The 5-8 membered heterocyclic group is selected from oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydropyrrolyl, piperidinyl, piperazinyl or morpholinyl; the 5-8 membered heterocyclic group is optionally further substituted by one or more groups selected from halogen, C1-C6 alkyl.

14. The compound represented by general formula (II) or a pharmaceutically acceptable salt thereof according to claim 11, wherein: R a and R b Together with the nitrogen atom to which they are attached, they form a 5- to 8-membered heterocyclic group, wherein the 5- to 8-membered heterocyclic group is selected from phospholyl; the 5- to 8-membered heterocyclic group is optionally further substituted by one or more groups selected from C1-C6 alkyl.

15. The compound represented by general formula (II) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 14, wherein the compound is selected from:

16. A method for preparing the compound represented by general formula (II) or a pharmaceutically acceptable salt thereof according to claim 1, comprising the following steps: In the presence of a condensation agent, compound IIg and IIh are subjected to a condensation reaction under alkaline conditions to obtain a compound of formula (II); Among them, A 1 , A 2 , A 3 , A 4 , A 5 , R 1 , R 2 , R 3 , L, n as defined in claim 1.

17. The method according to claim 16, wherein the basic condition is DIPEA and the condensing agent is HATU.

18. A pharmaceutical composition comprising a compound represented by general formula (II) according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

19. Use of the compound represented by general formula (II) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 15 or the pharmaceutical composition according to claim 18 in the preparation of a P2X3 antagonist.

20. Use of the compound represented by general formula (II) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 15 or the pharmaceutical composition according to claim 18 in the preparation of a medicament for preventing and / or treating a disease associated with P2X3 activity.

21. The use according to claim 20, wherein the disease associated with P2X3 activity is selected from respiratory system diseases, urogenital system diseases, digestive system diseases, nervous system diseases, musculoskeletal system diseases, circulatory system diseases and pain.

22. The use according to claim 21, wherein the respiratory system disease is emphysema, asthma, bronchospasm, pulmonary fibrosis, acute cough or chronic cough; the genitourinary system disease is endometriosis, uterine fibroids, dysmenorrhea, pelvic inflammatory disease, urethritis, cystitis, overactive bladder, prostatic hyperplasia, prostatitis, orchitis or dyspareunia; the digestive system disease is irritable bowel syndrome, ulcerative colitis, Crohn's disease, biliary colic, functional bowel disease, gastroesophageal reflux, gastric dilatation and colon dilatation; the nervous system disease is epilepsy, neuritis, neuropathy, Alzheimer's disease, Parkinson's disease; the musculoskeletal system disease is gout, arthritis; the circulatory system disease is cerebral ischemia, traumatic brain injury or myocardial infarction.

23. The use according to claim 22, wherein the arthritis is osteoarthritis.

24. The use according to claim 21, wherein the respiratory disease is chronic obstructive pulmonary disease.

25. The use according to claim 21, wherein the urogenital disease is urinary incontinence.

26. The use according to claim 21, wherein the musculoskeletal disease is rheumatoid arthritis or ankylosing spondylitis.

Citation Information

Patent Citations

  • P2x3 receptor antagonists for treatment of pain

    WO2010111059A1

  • Amide compounds, compositions and uses thereof

    CN101981003A

  • 1,3-thiazol-2-yl substituted benzamides

    CN107207507A

  • Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1R)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide

    CN114026086A

  • New amide derivative and salt thereof

    JP1999349572A

Cited By

  • P2X3 inhibitors and uses thereof

    CN114591317A

  • P2X3 inhibitors and uses thereof

    CN114591317B